Adlai Nortye Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-4.5%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.30next fiscal year
Monitoring Framework
Key Performance Indicators
Dose escalation completion of Phase 1 trial for oral pan-RAS(ON) inhibitor AN9025 AnnuallyTarget: H1 2027
IND submission for CEACAM5-targeting ADC AN4035 AnnuallyTarget: Mid-2026
Watch Items
- Clinical development progress of oral pan-RAS(ON) inhibitor AN9025Trigger: Completion of Phase 1 dose escalation in H1 2027Action: Evaluate Phase 1 safety, tolerability, and preliminary efficacy data to determine advancement to Phase 2 trials.
- IND clearance and Phase 1 trial initiation for CEACAM5-targeting ADC AN4035Trigger: IND submission in mid-2026Action: Monitor FDA/NMPA regulatory feedback and track first patient dosing timelines.
Research as of 19 Jun 2026